PROM1 and vulva cancer: Percentages of PD-L1+ CD49f+ CD133+ CTCs increased after aRT in patients with vulvar cancer (Fig. 3G; dark orange dots; 1.3-fold) as well as after aCRT (Fig. 3H; dark blue dots; 1.3-fold) and pCRT (dark red dots; 1.6-fold) in patients with cervical cancer compared to baseline.